Business Wire

Toshiba Launches New ELERA™ Security Suite to Address the Industry’s Challenges Around Shrink

12.9.2023 16:05:00 EEST | Business Wire | Press release

Share

The new ELERA Security Suite from Toshiba Global Commerce Solutions empowers retailers to minimize shrink while providing consumers with enhanced checkout experiences and reduced friction. According to the latest data from the National Retail Federation, retail shrink accounted for $94.5 billion in losses in 2021 in the U.S. and continues to be a critical challenge for retailers. Available later this year, the ELERA™ Security Suite offers retailers a comprehensive solution to protect their bottom line and combat multiple forms of shrink.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912900113/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The A.I.-powered ELERA™ Security Suite offers retailers a comprehensive solution to minimize shrink while providing consumers with enhanced checkout experiences. (Photo: Business Wire)

“In a world where every second and every cent counts, ELERA™ Security Suite is not just a tool but a strategy—turning data into decisions and losses into profits,” said Yevgeni Tsirulnik, SVP of Innovation and Incubation at Toshiba Global Commerce Solutions. “As global leaders in retail solutions, our Toshiba team and partners came together to envision and develop the A.I.-powered ELERA Security Suite to enhance their loss prevention measures that have a direct and positive impact on retailer profits while also improving the shopper experience.”

The ELERA Security Suite end-to-end solution deployed as-a-service through Toshiba’s IoT platform, fully orchestrates computer vision cameras with advanced edge A.I., to enhance profit protections and shopper experiences through:

  • Monitoring consumer behavior in real-time – without servers or processing lag – via TCx® EDGEcam+ and multiple sensors, which adds enhanced security throughout the checkout area
  • Responding to incidents as they occur for more impactful and timely resolutions with leading A.I.-powered computer vision
  • Notifying shoppers of potential errors through proactive alerts and allowing them to correct the issue themselves – minimizing employee intervention and improving the checkout experience
  • Differentiating customer’s items vs. store items they’re purchasing, improving recognition accuracy, and reducing incorrect warnings

The modular ELERA Security Suite system empowers retailers with versatility and opportunities to leverage the latest technology to meet their business needs. The ELERA Security Suite can be part of the overall ELERA™ solution, or it can be attached to other Toshiba or third-party POS systems.

“We are excited to expand our collaboration with Toshiba Global Commerce Solutions by integrating the Qualcomm® QRB5165 System-on-Chip (SoC) for IoT into Toshiba’s TCx EDGEcam+ to provide one of the best A.I. edge processing platforms in the market,” stated Art Miller, Vice President, Business Development and Head of Retail and Payments, Qualcomm Technologies, Inc. “Qualcomm QRB5165 SoC brings distributed A.I. and compute capabilities to the edge eliminating the need for expensive and power-intensive servers in the back of the store.”

This A.I.-driven solution presents benefits to both retailers and consumers across multiple touchpoints. ELERA™ Security Suite expands on the previously available ELERA™ Produce Recognition that leverages A.I. and computer vision to accurately and efficiently identify produce and eliminate the need to input produce codes at checkout manually. Retailers are already benefiting from the produce recognition innovation through improved inventory accuracy and throughput in the self-service experience enabling a more seamless checkout and positive consumer experience. Based on recent retailer data, Toshiba has found that shoppers save as much as five seconds per produce item lookup during checkout.

Retailers that invest in the ELERA Security Suite can see strong returns on their investment in this new technology suite through increased inventory accuracy, decreased store staff intervention, and increased adoption of their self-checkout lanes. Given Toshiba’s focus on retailers and consumer privacy, we also offer peace of mind by meeting the requirements of applicable data privacy laws, including all federal, state, regional, territorial, national, and local laws, regulations, and rules by any government agency or authority that relate to the processing or the security of personal data.

Toshiba experts will be at GroceryShop 2023 in Las Vegas from September 19-21 to showcase the ELERA Security Suite and a portfolio of other retail solutions that enable retailers to re-imagine, accelerate, and differentiate their shopping experiences (booth #1050).

About Toshiba Global Commerce Solutions

Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs. Visit commerce.toshiba.com and engage with us on X, formerly known as Twitter, Facebook, LinkedIn, Instagram, and YouTube, to learn more.

Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.

Qualcomm

Qualcomm is a trademark or registered trademark of Qualcomm incorporated. Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Toshiba Global Commerce Solutions
Elizabeth Romero
Director, Corporate Communications
elizabeth.romero@toshibagcs.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye